Multispecific Antibody Affinity Engineering for CD3 Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multispecific antibodies face challenges in effectively targeting CD3, BCMA, and CD38 simultaneously, which is crucial for therapeutic applications such as cancer treatment, as they often activate T cells unsafely or have imbalanced affinities that reduce efficacy and increase immune response risks.
Innovation Solution
Development of multispecific antibodies or antigen-binding fragments with carefully adjusted affinities and structures, including heavy-chain antibody variable domains (VHH) and light chain variable regions (VL), that specifically bind to CD3, BCMA, and CD38, ensuring high affinity to cancer antigens and low affinity to CD3 to prevent unwanted T-cell activation, utilizing specific amino acid sequences and structural formats like BiSpecific-V0, TriSpecific-V1, and scFv configurations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multispecific antibodies are designed to simultaneously bind to CD3, BCMA, and CD38 with high affinity, then therapeutic efficacy is improved, but safety deteriorates due to unwanted T-cell activation
Solution Approach 1:
The patent applies local quality by designing different antigen-binding domains with distinct affinity characteristics within the same multispecific antibody molecule. Specifically, the antibody contains high-affinity binding sites for cancer antigens (BCMA and/or CD38) and low-affinity binding sites for CD3, creating localized functional differences that enable selective T-cell activation only when cancer antigens are present. This resolves the contradiction by making the antibody's binding properties non-uniform across different targets.
Solution Approach 2:
The patent employs parameter changes by carefully adjusting the affinity parameters of the antibody's binding sites. The CD3-binding domain is engineered with specifically optimized affinity parameters that are lower than those of the cancer antigen-binding domains. This parameter differentiation ensures that the antibody can bind to cancer cells with high affinity while binding to T cells with lower affinity, thereby preventing unwanted T-cell activation unless the antibody is presented in the context of cancer antigens.
2Ease of manufacture
If multisspecific antibodies use conventional antibody structures, then ease of manufacture is improved, but manufacturing precision deteriorates due to imbalanced affinities
Solution Approach 1:
The patent applies composite materials by constructing the multispecific antibody from heterogeneous antigen-binding domains with different structural and functional characteristics. The antibody comprises a combination of heavy-chain antibody variable domains (VHH) and conventional variable regions (VH and/or VL), each engineered to bind different antigens with specific affinity profiles. This composite structure allows independent optimization of binding affinities for each antigen while maintaining overall molecular stability and manufacturability.
Solution Approach 2:
The patent employs segmentation by dividing the antibody into distinct functional modules, each responsible for binding a specific antigen. The multispecific antibody is segmented into separate antigen-binding domains for CD3, BCMA, and/or CD38, with each domain independently engineered to achieve the desired affinity balance. This modular segmentation enables precise control over binding characteristics while simplifying the manufacturing process through standardized domain construction.
Data Source
AI summary
This disclosure relates to multispecific antibodies (e.g., bispecific antibodies) or antigen-binding fragments thereof. In one aspect, the multispecific antibodies or antigen-binding fragments thereof binds to CD3, BCMA, and/or CD38, or a combination thereof.